Semaxanib (SUGEN)

SUGEN (owned by Pharmacia) is developing semaxanib (SU-5416), the lead in a series of small molecule inhibitors of the flk-1 tyrosine kinase receptor (flk-1 RTK), for the potential treatment of solid tumors (via suppression of metastasis and angiogenesis) [191353], [264484]. In July 1999, phase III trials for colorectal and lung cancer were initiated [326969]. In March 2001, phase III trials were initiated for the compound as an addition to a standard chemotherapy regimen in colorectal cancer [402241]; at this time, Pharmacia, as well as the NCI, was conducting clinical studies for numerous other solid and hematological cancers [402241]. By October 2000, oral forms of the compound were also being evaluated [385699]. In July 2000, Pharmacia anticipated US and international filing in 2001 [374505]. Taiho and SUGEN have agreed a joint development program for SUGEN's angiogenesis inhibitors [293021]. In August 1998, the USPTO issued US-05792783 to SUGEN, covering a family of compounds, including semaxanib. The patent claims cover the compounds and composition, as well as methods of use in a variety of diseases, including cancer [294467]. In August 1998, the USPTO issued US-05792783 to SUGEN, covering a family of compounds, including semaxanib. The patent claims cover the compounds and composition, as well as methods of use in a variety of diseases, including cancer [294467].